Phase 3 Recruiting NIH
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Rochester — Rochester, New York
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in New York: - Albany Medical Center — Albany, New York
- Maimonides Medical Center — Brooklyn, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- Mount Sinai Hospital — New York, New York
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in New York: - Albany Medical Center — Albany, New York
- Roswell Park Cancer Institute — Buffalo, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
Phase 3 Recruiting Network
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…
Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in New York: - Albany Medical Center — Albany, New York
- Roswell Park Cancer Institute — Buffalo, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- Mount Sinai Hospital — New York, New York
Phase 3 Recruiting Network
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Issac Perlmutter Ca Ctr at NYU Langone — New York, New York
- University of Rochester — Rochester, New York
- Stony Brook University Medical Center — Stony Brook, New York
Phase 3 Recruiting Industry
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Sponsor: Polaris Group
NCT ID: NCT05712694
Sites in New York: - NYU Langone Health — New York, New York
- Columbia University — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Indepe…
Sponsor: PharmaMar
NCT ID: NCT06088290
Sites in New York: - Memorial Sloan Kettering Cancer Center - New York — New York, New York
Phase 3 Recruiting Industry
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride…
Sponsor: Advenchen Laboratories, LLC
NCT ID: NCT03016819
Sites in New York: - Columbia University Medical Center — New York, New York
Phase 3 Recruiting Industry
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in New York: - New York Oncology Hematology, P.C. ( Site 0132) — Albany, New York
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Sites in New York: - Investigative Site — New York, New York
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in New York: - Local Institution - 2117 — New York, New York
- Local Institution - 1002 — New York, New York
- Local Institution - 2102 — New York, New York
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Laura and Isaac Perlmutter Cancer Center / NYU Langone Health — New York, New York
- Columbia University Medical Center — New York, New York
- University of Rochester Wilmot Cancer Institute — Rochester, New York
- Montefiore Medical Center — The Bronx, New York
Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
Sponsor: Pierre Fabre Medicament
NCT ID: NCT04554914
Sites in New York: - Columbia University Irving Medical Center (Adults only) — New York, New York
- Memorial Sloan-Kettering Cancer Center (Adults and Pediatrics) — New York, New York
- The Children's Hospital at Montefiore (Adults and Pediatrics) — The Bronx, New York
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people wi…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05634369
Sites in New York: - Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Montefiore Medical Center — The Bronx, New York
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in New York: - Local Institution - 2102 — New York, New York
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in New York: - Memorial Sloan Kettering Cancer Center ( Site 1010) — New York, New York
- New York Medical College ( Site 1023) — Valhalla, New York
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in New York: - New York University Langone Health — New York, New York
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05985161
Sites in New York: - Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ) — Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All protocol activites) — New York, New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) — Rockville Centre, New York
Phase 1, Phase 2 Recruiting Industry
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants wi…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05734066
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Academic/Other
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activat…
Sponsor: Carl Allen
NCT ID: NCT04079179
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Network
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sponsor: AIDS Malignancy Consortium
NCT ID: NCT04305691
Sites in New York: - Mount Sinai Hospital — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Sponsor: USWM CT, LLC
NCT ID: NCT05642455
Sites in New York: - Memorial Sloan Kettering Kids — New York, New York
Phase 1, Phase 2 Recruiting Academic/Other
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention. Phase I studies also try to define the appropriate dose of the investigational therapy to use for further studies.…
Sponsor: Massachusetts General Hospital
NCT ID: NCT01659203
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called isolated lim…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT04332874
Sites in New York: - Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York